NCT03108066
- Conditions
- Abnormalities, Multiple, Adenocarcinoma, Angiomatosis, +35 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
Clinical trial condition
VHL Gene Inactivation
Explore clinical trials studying VHL Gene Inactivation. Study availability and eligibility vary by location and protocol.
2 public trials
0 recruiting studies
VHL Gene Inactivation trial results
Active, Not Recruiting
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
NCT03401788
- Conditions
- Abnormalities, Multiple, Angiomatosis, Cardiovascular Diseases, +14 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
- Massachusetts General Hospital Boston, Massachusetts, United States
- University of Michigan Ann Arbor, Michigan, United States
- University of Pennsylvania Medical Center Philadelphia, Pennsylvania, United States